Research Article

Biginelli Synthesis of Novel Dihydropyrimidinone Derivatives Containing Phthalimide Moiety

Mashooq A. Bhat, Mohamed A. Al-Omar, Ahmed M. Naglah, and Abdullah Al-Dhfyan

1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
2Drug Exploration and Development Chair, Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
3Peptide Chemistry Department, Chemical Industries Research Division, National Research Centre, 12622 Dokki, Cairo, Egypt
4Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

Correspondence should be addressed to Mashooq A. Bhat; mabhat@ksu.edu.sa

Received 31 October 2019; Accepted 10 February 2020; Published 9 March 2020

1.Introduction

Pyrimidines have played a vital role in the field of pharmaceutical chemistry [1]. Pyrimidines are important moiety because of their various pharmacological activities. Nifedipine, 4-aryl-1,4-dihydropyridines, was the first antihypertensive agent into the clinical medicine. For the treatment of various cardiovascular diseases, dihydropyridines are the most potent calcium channel blockers [2, 3].

Substituted dihydropyrimidinone compounds show interesting biological properties, e.g., calcium channel blockers and antihypertensive agents [4, 5]. These compounds display a broad spectrum of biological activities such as anti-inflammatory, antitumor, antiviral, and antibacterial ones [6, 7]. Dihydropyrimidinone compounds were first synthesized by Pietro Biginelli. The type of compounds is known as Biginelli compounds. The synthesis of this type of compounds involves the reacting of numerous aldehydes with urea and a beta-keto ester to give a tetrahydropyrimidinone.

Phthalimide analogues have been reported with large range of pharmacological activities that are anticonvulsant, anti-inflammatory, analgesic, and hypolipidemic [8–11]. Phthalimide analogues have been synthesized as tumor necrosis factor-α (TNF-α) inhibitors [12]. TNF-α plays an important role in certain physiological immune systems. It stimulates the inflammatory response leading to autoimmune disorders including rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, psoriasis, and refractory asthma [13]. Extensive research on the phthalimide analogues has been reported in the literature [14–17].

The hybrid compounds containing these two important moieties (dihydropyrimidinone and phthalimide) may have
2. Experiment

2.1. Chemistry. Solvents were procured from Merck, New Jersey, USA. Thin layer chromatography (TLC) was performed on Silica gel 60F254 coated plates (Merck, Millipore, Billerica, MA, USA) to check the purity of compounds. For performing FT-IR, PerkinElmer FT-IR spectrophotometer (PerkinElmer Inc., Waltham, MA, USA) was used. Melting points were determined by Gallenkamp melting point apparatus. 1H and 13C NMR were recorded in Bruker NMR 500/700 MHz and 125/176 MHz spectrophotometer (Bruker Corporation, Billerica, MA, USA). The samples were dissolved in DMSO-d6 with tetramethylsilane (TMS) as an internal standard. The molecular masses of compounds were determined by Agilent triple quadrupole 6410 TQ GC/MS equipped with ESI (electrospray ionization) source (5301 Stevens Creek Blvd, Santa Clara, CA 95051, USA). The CHN (Elementar Analysensysteme GmbH, Langenselbold, Germany) was used for elemental analysis of the compounds.

Scheme 1 depicts a reaction by which the dihydropyrimidinone derivatives of phthalimide were prepared. The dihydropyrimidinone derivatives (1–10) were synthesized by refluxing phthalic anhydride (I) followed by reaction mixture was cooled to room temperature. Diethyl ether was added to precipitate the reaction mixture and vacuum filtration was performed. The obtained product was recrystallized from glacial acetic acid and ethanol.

2.2. Synthesis of the Dihydropyrimidinone Derivatives (1–10). A mixture of enamine, 2-[4-[(dimethylamino) prop-2-enoyl]phenyl]-1H-isooindole-1,3(2H)-dione (IV) (0.01 mol), differently substituted benzaldehyde (0.01 mol), urea (0.01 mol), and glacial acetic acid (10 mL), was refluxed for 3 h. The precipitates (1–10) were obtained by adding ice cold water to the reaction mixture. The products were obtained by filtration under vacuum. The products were washed several times with water. The products were purified by recrystallization from glacial acetic acid and ethanol mixture. The physicochemical properties of compounds (1–10) are given in Table 1.

2.2.1. 5-Benzoyl-3,4-dimethoxyphenyl-3,4-dihydropyrimidin-2(1H)-one-1H-isooindole-1,3(2H)-dione (I). m.p.: 190–192°C; 1H NMR (500 MHz, DMSO-d6): δ = 3.81 (3H, s, -OCH3), 3.89 (3H, s, -OCH3), 5.76 (1H, s, H-4), 6.94–7.99 (12H, m, Ar-H), 9.36 (1H, s, CONH, D2O exchg.), 10.31 (1H, s, NH, D2O exchg.); 13C NMR (125.76 MHz, DMSO-d6): δ = 49.8, 56.5, 56.6, 60.0, 62.4, 65.4, 112.3, 112.6, 118.7, 120.2, 123.9, 124.4, 127.4, 129.0, 131.9, 134.4, 135.2, 137.3, 138.4, 146.6, 146.6, 151.4, 152.9, 167.2, 190.4, 191.1; MS: m/z = 483.47 [M]+; Analysis: for C27H21N3O6 calcd. C 67.07, H 4.39, N 8.69%; Found C 67.26, H 3.27, N 8.67%.

2.2.2. 5-Benzoyl-4-nitrophenyl-3,4-dihydropyrimidin-2(1H)-one-1H-isooindole-1,3(2H)-dione (2). m.p.: 210–212°C; 1H NMR (500 MHz, DMSO-d6): δ = 6.02 (1H, s, H-4), 7.09–8.19 (13H, m, Ar-H), 9.60 (1H, s, CONH, D2O exchg.), 10.16 (1H, s, NH, D2O exchg.); 13C NMR (125.76 MHz, DMSO-d6): δ = 117.1, 123.9, 124.7, 128.4, 129.1, 131.0, 131.9, 134.6, 135.2, 138.0, 140.5, 143.3, 147.2, 151.5, 167.2, 191.1, 192.7, 207.0; MS: m/z = 468.41 [M]+; Analysis: for C25H22N2O5 calcd. C 67.26, H 4.39, N 8.69%; Found C 67.27, H 4.35, N 11.94%.

2.2.3. 5-Benzoyl-3-nitrophenyl-3,4-dihydropyrimidin-2(1H)-one-1H-isooindole-1,3(2H)-dione (3). m.p.: 240–242°C; 1H NMR (500 MHz, DMSO-d6): δ = 5.64 (1H, s, H-4), 7.22–8.22 (13H, m, Ar-H), 9.60 (1H, s, CONH, D2O exchg.); 13C NMR (125.76 MHz, DMSO-d6): δ = 111.6, 121.7, 123.0, 124.0, 127.4, 129.1, 131.9, 133.7, 134.6, 135.2, 138.0, 146.5, 148.3, 151.3, 167.2, 191.2; MS: m/z = 468.41 [M]+; Analysis: for C25H16N4O6 calcd. C 64.10, H 3.44, N 11.96%; Found C 64.28, H 3.45, N 11.98%.

2.2.4. 5-Benzoyl-2-nitrophenyl-3,4-dihydropyrimidin-2(1H)-one-1H-isooindole-1,3(2H)-dione (4). m.p.: 170–172°C; 1H NMR (500 MHz, DMSO-d6): δ = 6.17 (1H, s, H-4), 7.22–7.98 (13H, m, Ar-H), 9.62 (1H, s, CONH, D2O exchg.), 10.30 (1H, s, NH, D2O exchg.); 13C NMR (125.76 MHz, DMSO-d6): δ = 111.6, 123.9, 124.5, 127.3, 129.3, 130.0, 131.9, 134.5, 135.2, 137.7, 138.5, 143.3, 148.3, 150.9, 167.1, 191.0; MS: m/z = 468.41 [M]+; Analysis: for C25H16N4O6 calcd. C 64.10, H 3.44, N 11.96%; Found C 64.27, H 3.46, N 11.94%.

2.2.5. 5-Benzoyl-2,3-dimethoxyphenyl-3,4-dihydropyrimidin-2(1H)-one-1H-isooindole-1,3(2H)-dione (5). m.p.: 190–192°C; 1H NMR (500 MHz, DMSO-d6): δ = 3.81 (3H, s, -OCH3), 3.89 (3H, s, -OCH3), 5.76 (1H, s, H-4), 6.94–7.99 (12H, m, Ar-H), 9.36 (1H, s, CONH, D2O exchg.), 10.31 (1H, s, NH, D2O exchg.); 13C NMR (125.76 MHz, DMSO-d6): δ = 49.8, 56.5, 56.6, 60.0, 62.4, 65.4, 112.3, 112.6, 118.7, 120.2, 123.9, 124.4, 127.4, 129.0, 131.9, 134.4, 135.2, 137.3, 138.4, 146.6, 146.6, 151.4, 152.9, 167.2, 190.4, 191.1; MS: m/z = 483.47 [M]+; Analysis: for C27H21N3O6 calcd. C 64.10, H 4.39, N 11.96%; Found C 64.26, H 3.43, N 11.97%.

2.2.6. 5-Benzoyl-4,5-trimethoxyphenyl-3,4-dihydropyrimidin-2(1H)-one-1H-isooindole-1,3(2H)-dione (6). m.p.: 180–182°C; 1H NMR (500 MHz, DMSO-d6): δ = 3.69 (3H, s, -OCH3), 3.79 (3H, s, OCH3), 3.84 (3H, s, OCH3), 5.60 (1H, s, H-4), 6.73–8.00
2.2.7. 5-Benzoyl-3,4,5-trimethoxyphenyl-3,4-dihydropyrimidin-2(1H)-one-1H-isoindole-1,3(2H)-dione (7). m.p.: 195–197°C; 1H NMR (500 MHz, DMSO-d_6): δ = 3.66 (3H, s, -OCH_3), 3.79 (3H, s, OCH_3), 3.94 (3H, s, OCH_3), 5.65 (1H, s, H-4), 6.77–7.99 (11H, m, Ar-H), 9.36 (1H, s, CONH, D_2O exchg.), 10.12 (1H, s, NH, D_2O exchg.); 13C NMR (125.76 MHz, DMSO-d_6): δ = 45.0, 55.5, 56.3, 56.5, 65.0, 91.1, 91.6, 93.2, 111.5, 112.9, 123.9, 131.1, 139.1, 142.2, 152.0, 159.6, 160.6, 161.6, 163.8, 167.1, 186.1, 191.2; MS: m/z = 513.49 [M]^+; Analysis: for C_{28}H_{23}N_{3}O_{7} calcd. C 65.49, H 4.51, N 8.18%; Found C 65.46, H 4.52, N 8.16%.

2.2.8. 5-Benzoyl-2,3,4-trimethoxyphenyl-3,4-dihydropyrimidin-2(1H)-one-1H-isoindole-1,3(2H)-dione (8). m.p.: 165–167°C; 1H NMR (500 MHz, DMSO-d_6): δ = 3.78 (3H, s, -OCH_3), 3.79 (3H, s, OCH_3), 3.94 (3H, s, OCH_3), 5.65 (1H, s, H-4), 6.77–7.99 (11H, m, Ar-H), 9.36 (1H, s, CONH, D_2O exchg.), 10.12 (1H, s, NH, D_2O exchg.); 13C NMR (125.76 MHz, DMSO-d_6): δ = 45.0, 55.5, 56.3, 56.5, 65.0, 91.1, 91.6, 93.2, 111.5, 112.9, 123.9, 131.1, 139.1, 142.2, 152.0, 159.6, 160.6, 161.6, 163.8, 167.1, 186.1, 191.2; MS: m/z = 513.49 [M]^+; Analysis: for C_{28}H_{23}N_{3}O_{7} calcd. C 65.49, H 4.51, N 8.18%; Found C 65.36, H 4.49, N 8.16%.

2.2.9. 5-Benzoyl-2,4,6-trimethoxyphenyl-3,4-dihydropyrimidin-2(1H)-one-1H-isoindole-1,3(2H)-dione (9). m.p.: 155–157°C; 1H NMR (500 MHz, DMSO-d_6): δ = 3.69 (3H, s, -OCH_3), 3.70 (3H, s, OCH_3), 3.82 (3H, s, OCH_3), 5.65 (1H, s, H-4), 6.77–7.99 (11H, m, Ar-H), 9.36 (1H, s, CONH, D_2O exchg.), 10.12 (1H, s, NH, D_2O exchg.); 13C NMR (125.76 MHz, DMSO-d_6): δ = 45.2, 55.5, 56.3, 56.5, 65.4, 91.1, 91.6, 93.2, 111.5, 112.9, 123.9, 127.2, 128.9, 131.9, 135.2, 139.1, 142.2, 152.0, 159.6, 160.6, 161.6, 167.2, 186.1, 191.2; MS: m/z = 513.49 [M]^+; Analysis: for C_{28}H_{23}N_{3}O_{7} calcd. C 65.49, H 4.51, N 8.18%; Found C 65.59, H 4.50, N 8.20%.

2.2.10. 5-Benzoyl-2,4-dimethoxyphenyl-3,4-dihydropyrimidin-2(1H)-one-1H-isoindole-1,3(2H)-dione (10). m.p.: 168–170°C; 1H NMR (500 MHz, DMSO-d_6): δ = 3.75 (3H, s, -OCH_3), 3.84 (3H, s, OCH_3), 5.66 (1H, s, H-4), 6.59–8.00 (12H, m, Ar-H), 9.33 (1H, s, CONH, D_2O exchg.), 10.12 (1H, s, NH, D_2O exchg.); 13C NMR (125.76 MHz, DMSO-d_6): δ = 49.1, 55.6, 56.0, 65.4, 99.1, 104.9, 111.5, 123.8, 124.0, 127.4, 127.5, 127.9, 131.0, 139.1, 134.4, 135.2, 138.5, 142.9, 151.8, 158.4, 160.5, 167.0, 191.0; MS: m/z = 483.47 [M]^+; Analysis: for C_{27}H_{21}N_{3}O_{6} calcd. C 67.07, H 4.38, N 8.69%; Found C 66.82, H 4.39, N 8.70%.

3. Results and Discussion

As shown in Scheme 1, enaminone, 2-{4-[(2E)-3-(dimethylamino) prop-2-enoyl] phenyl}-1H-isoindole-1,3(2H)-dione (IV), was synthesized by refluxing 2-(4-acetylphenyl)-1H-
isoindole-1,3(2H)-dione (III) with dimethylformamide-dimethylacetal (DMF-DMA) under solvent-free conditions for 12 h. To prepare the final dihydropyrimidinone derivatives, a mixture of substituted benzaldehyde (0.01 mol), enaminone (IV) (0.01 mol), urea (0.01 mol), and glacial acetic acid (10 mL) was heated under reflux for 3 h. The ethylenic protons indicate that the enaminone existed in the \(E\)-configuration [20]. Compounds presented the \(D_2O\) exchangeable broad singlet at \(\delta\) 9.33–9.62 ppm and \(\delta\) 10.12–10.31 ppm corresponding to the two NH protons. The H-4 protons of dihydropyrimidinone moiety and aromatic protons were observed at \(\delta\) 5.43–6.17 and \(\delta\) 6.59–8.41 ppm, respectively [21]. \(^{13}\)C NMR spectra confirmed all the carbon atoms for compounds (1–10). Molecular weights of the compounds were confirmed by mass spectral data. Molecular ion peaks were observed in all compounds respective to their molecular weights. The composition of the synthesized compounds (1–10) was confirmed by spectral and elemental data. The possible reaction mechanism involves the acid catalyzed formation of iminium ion intermediate from the substituted aryl aldehydes and urea. Reaction of phthalimide enaminone by iminium ion yields ureidenone, which forms hexahydropyrimidine by cyclization. Final dihydropyrimidinone derivatives (1–10) were obtained by elimination of NH(CH\(_3\))\(_2\) group from hexahydropyrimidine in presence of glacial acetic acid (Scheme 2).

**4. Conclusion**

In conclusion, a series of novel dihydropyrimidinone derivatives containing phthalimide moiety were synthesized in good yield, at high level of purity, and in efficient manner from the enaminone, which was derived from phthalimide by simple and solvent-free method. The enaminone existed in the \(E\)-configuration. All the compounds were characterized and confirmed by different spectroscopic methods and elemental analysis.

**Data Availability**

Samples of the compounds (1–10) in pure form are available from the authors upon request.

**Scheme 2**: The possible mechanism for the synthesis of dihydropyrimidinone derivatives containing phthalimide (1–10).
Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for funding this research group (No. RG 1435-006).

References


